OOIR: Observatory of International Research

Papers

(The H4-Index of British Journal of Haematology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	101
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation	93
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma	92
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry	89
Updates on targeted therapies for acute myeloid leukaemia	82
Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience	81
Increased CD95 (Fas) and PD‐1 expression in peripheral blood T lymphocytes in COVID‐19 patients	78
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies	76
Disseminated intravascular coagulation: epidemiology, biomarkers, and management	76
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations	73
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination	71
Impact of COVID‐19 on red blood cell rheology	69
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy	67
Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series	66
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma	65
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity	65
Emicizumab treatment and monitoring in a paediatric cohort: real‐world data	62
Guidelines on the use of irradiated blood components	62
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?	57
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy	56
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies	55
COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies	52
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma	52
A national service for delivering CD19 CAR‐Tin large B‐cell lymphoma – The UK real‐world experience	51
MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a pros	50

Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic mye	50
Immunogenicity and safety of the BNT162b2 mRNA COVID‐19 vaccine in haematopoietic stem cell transplantation recipients	50
COVID‐19 mortality in patients on anticoagulants and antiplatelet agents	49
Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients	49
Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐19	48
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising ant	46
Vacuoles in neutrophil precursors in VEXAS syndrome: diagnostic performances and threshold	46
Fostamatinib is an effective second‐line therapy in patients with immune thrombocytopenia	45
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells	45
Vaccine‐induced immune thrombotic thrombocytopenia (VITT) – a novel clinico‐pathological entity with heterogeneous clinical presentations	45
ABO phenotype and death in critically ill patients with COVID‐19	44
COVID‐19 and immunothrombosis: emerging understanding and clinical management	44
Non‐myeloablative human leukocyte antigen‐matched related donor transplantation in sickle cell disease: outcomes from three independent centres	44
Haemophagocytic lymphohistiocytosis and Epstein–Barr virus: a complex relationship with diverse origins, expression and outcomes	43
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study	42
Early mortality benefit with COVID‐19 convalescent plasma: a matched control study	42
Convalescent plasma for persisting COVID‐19 following therapeutic lymphocyte depletion: a report of rapid recovery	41
Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis	41